Biopharmaceutical company Jazz Pharmaceuticals plc (Nasdaq:JAZZ) said on Wednesday that it has submitted its New Drug Application (NDA) seeking marketing approval of JZP-258 for treating cataplexy under the US Food and Drug Administration's (FDA) Priority Review.
The Prescription Drug User Fee Act (PDUFA) goal date for the FDA's decision is 21 July 2020.
According to the company, JZP-258 is an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. It is a novel oxybate product candidate with a unique composition of cations resulting in 92%, or about 1,000 to 1,500 milligrams, less sodium than Xyrem (sodium oxybate). Xyrem is the only available product approved to treat both cataplexy and EDS in patients with narcolepsy aged 7 years and older and is the standard of care for treatment of cataplexy.
Cataplexy, the most specific symptom of narcolepsy, is the sudden, generally brief (
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT